Covid 19 Research using Clinical Trials (Home Page)
CAP-1002 Allogeneic Cardiosphere-Derived CellsWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (2)
Correlated MeSH Terms (2)
|
Name (Synonyms) |
Correlation |
D013315 | Stress, Psychological NIH | 0.21 |
D001008 | Anxiety Disorders NIH | 0.17 |
Correlated HPO Terms (0)
|
Name (Synonyms) |
Correlation |
There is one clinical trial.
Clinical Trials
This randomized, double-blind, placebo-controlled trial will enroll subjects with a clinical
diagnosis of COVID-19 confirmed by laboratory testing. Eligible subjects will be randomized
to either CAP-1002 or placebo in a 1:1 ratio. Intravenous administration of CAP-1002 or
placebo will occur at the clinical site on Day 1 and Day 7 (± 1 day) for a maximum of 2
doses, based on clinical course. Subjects will complete Screening, a Treatment Phase and a
Follow-up Phase. The Treatment Phase is variable based on each subject's clinical status
while the subject remains in the hospital and will contain either one or two treatment
periods.
Baseline safety and efficacy assessments will be conducted prior to the first infusion.
Follow-up will be conducted on Day 15 and Day 30 from the first infusion in Treatment Period
1. Subjects will be observed during the index hospitalization and monitored for outcome and
safety. Transthoracic echocardiograms will be performed when indicated by clinical or
laboratory evidence of cardiac involvement during the index hospitalization. Use of any
concomitant medications to treat COVID-19 will be documented.
Stopping rules on the subject-level and study-level have been defined to ensure subjects are
not exposed to significant risk. Oversight of the trial will be provided by independent
Clinical Event Committee (CEC), Data Safety Monitoring Board (DSMB), and Medical Monitor.
NCT04338347 COVID-19 Biological: CAP-1002 Allogeneic Cardiosphere-Derived Cells
No related HPO nodes (Using clinical trials)